British neobank Revolut seems to be eyeing a major valuation bump when it eventually goes public.

The company is targeting a market cap between $150 billion and $200 billion in an initial public offering, the Financial Times reported on Tuesday, citing anonymous investor sources.

The fintech giant, which secured a full banking license in the United Kingdom in March after years of waiting, was most recently valued at $75 billion, up from $45 billion in 2024, in a secondary share sale that made it one of Europe’s most valuable private tech companies.

Revolut’s co-founder and CEO, Nik Storonsky, last week said that the company’s IPO was at least “two years away,” according to Bloomberg.

According to PitchBook and the Financial Times, the company is working on another secondary share sale, scheduled for the second half of 2026, that would value it at more than $100 billion.

As of November 2025, the company had raised a total of $5.

89 billion, according to PitchBook.

Revolut reported revenue of $6 billion in the financial year ended December 31, 2025, up from $4 billion in 2024.

The company’s net profit grew to $1. 7 billion, up from $1 billion in 2024, and counted 68. 3 million retail customers at the end of 2025. Revolut declined to comment.

Founded in 2015, Revolut offers a range of services spanning multi-currency accounts, payment and transfer services, crypto products, insurance, and more.

The neobank has been pouring truckloads of cash into expanding its operations internationally, and recently applied for a banking license in the United States

Highlighted sentences link to their corresponding claims. Click any highlighted sentence to jump to its detailed analysis.
Highlight Colors Indicate Claim Quality:
✓ Healthy Claim - No fallacies or contradictions detected
⚠️ Minor Issues - Has contradictions or minor fallacies
🚨 Serious Issues - Multiple contradictions or severe fallacies
Quality Criteria: Claims are evaluated for logical fallacies and contradictions with other news sources. Green highlights indicate healthy claims suitable for reference.
Source